Alzheimer patients at Swedish clinics to be included in Phase 3 study of drug candidate BAN2401
Stockholm, March 3, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai will include Swedish clinics in the confirmatory Phase 3 study of the drug candidate BAN2401. The enrollment of patients with early Alzheimer’s disease will be carried out at memory clinics at four Swedish university hospitals. The global study was initiated in spring 2019 and, according to Eisai, results from the study are expected in 2022. BAN2401 is an antibody that helps the body to eliminate accumulations of misfolded amyloid beta protein. BAN2401 attacks